Late Infantile Neuronal Ceroid Lipofuscinosis

Acronym

Definition

LINCL

References in periodicals archive	?		Acronyms browser	?		Full browser	?
Significant recent events in 2009 included: * In January 2009, we completed the six-patient Phase I clinical trial of our HuCNS-SC[R] product candidate as a treatment for infantile and late infantile neuronal ceroid lipofuscinosis (NCL), also often referred to as Batten disease. StemCells Announces 2009 First Quarter Financial Results by Business Wire In January 2008, the Company completed enrollment and dosing of a six-patient Phase I clinical trial of its proprietary HuCNS-SC([R]) product candidate (purified human neural stem cells) as a treatment for infantile and late infantile neuronal ceroid lipofuscinosis (NCL, also often referred to as Batten disease) at Oregon Health & Science University (OHSU) Doernbecher Children's Hospital. StemCells Announces 2008 First Quarter Results by Business Wire Highlights for 2007 and significant events since the end of the year include: * In January 2008, we completed enrollment and dosing of a six-patient Phase I clinical trial of our HuCNS-SC([R]) product candidate (purified human neural stem cells) as a treatment for infantile and late infantile neuronal ceroid lipofuscinosis (NCL, also often referred to as Batten disease) at Oregon Health & Science University (OHSU) Doernbecher Children's Hospital. StemCells Announces 2007 Fourth Quarter and Year End Results by Business Wire	LAT/LONG LATA LATAC LATADS LATAF LATAG LATAGS LATAM LATAN LATAR LATARS LATAS LATB LATBR LATC LATCC LATCF LATCH LATCO LATCP LATD LATDB LATDC LATDIR LATE Late Infantile Neuronal Ceroid Lipofuscinosis LATE-PCR LATEC LATECE LATEM LATER LATESLAV LATEST LATEU LATEX LATF LATFACS LATFB Latg LATGA LATGW LATH LATHC LATI LATIA LATIE LATIFPA LATIMS LATIN LATIS LATISS	Late fee Late Fees Late fine Late Finish Late Flank Alarm Late Flank Gate Late for a Date Late for Dinner Late French Immersion late gene Late Georgian style Late Glacial Period Late Gothic Late Gothic Revival Late Greek Late Greek Late Greek Late Hebrew Late Hebrew Late Hemorrhagic Disease of the Newborn late in life Late in Mid October Late in the Day Late in the Day Late in the Day Late in the Day late in the game late in the game late in the game Late Incremental Insulin Area Late Infantile Neuronal Ceroid Lipofuscinosis Late Intake Valve Closing Late Iron Age Late Iron Age Late Jurassic late lamented Late Latin Late Latin Late Latin Late leakage of undetermined source Late Life Function and Disability Instrument Late Life Parent Late Luteal Phase Disorder Late Luteal Phase Dysphoric Disorder Late Luteal Phase Dysphoric Disorder Late Medieval Period Late Midcourse Late Middle Chinese Late Minoan Late Minoan Late Minoan Late Mississippian Late Model Bus Organization, International Late Model Mustang Club of Connecticut Late Model Mustang Owners Association Late Modern English Late Modern English Late neoclassicism Late neoclassicism Late Neolithic Late Neolithic

References in periodicals archive

Acronyms browser

Full browser

Significant recent events in 2009 included: * In January 2009, we completed the six-patient Phase I clinical trial of our HuCNS-SC[R] product candidate as a treatment for infantile and late infantile neuronal ceroid lipofuscinosis (NCL), also often referred to as Batten disease.

StemCells Announces 2009 First Quarter Financial Results by Business Wire

In January 2008, the Company completed enrollment and dosing of a six-patient Phase I clinical trial of its proprietary HuCNS-SC([R]) product candidate (purified human neural stem cells) as a treatment for infantile and late infantile neuronal ceroid lipofuscinosis (NCL, also often referred to as Batten disease) at Oregon Health & Science University (OHSU) Doernbecher Children's Hospital.

StemCells Announces 2008 First Quarter Results by Business Wire

Highlights for 2007 and significant events since the end of the year include: * In January 2008, we completed enrollment and dosing of a six-patient Phase I clinical trial of our HuCNS-SC([R]) product candidate (purified human neural stem cells) as a treatment for infantile and late infantile neuronal ceroid lipofuscinosis (NCL, also often referred to as Batten disease) at Oregon Health & Science University (OHSU) Doernbecher Children's Hospital.

StemCells Announces 2007 Fourth Quarter and Year End Results by Business Wire